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Summary
The World Health Organization recommends universal iron
supplementation of 30–60 mg/day in pregnancy but coverage
is low in most countries. Its efficacy is uncertain, however,
and there has been a vigorous debate in the last decade about
its safety, particularly in areas with a high burden of malaria
and other infectious diseases. We reviewed the evidence on
the safety and efficacy of antenatal iron supplementation in
low-income countries. We found no evidence that daily sup-
plementation at a dose of 60 mg leads to increased maternal
Plasmodium infection risk. On the other hand, recent meta-
analyses found that antenatal iron supplementation provides
benefits for maternal health (severe anaemia at postpartum,
blood transfusion). For neonates, there was a reduced prema-
turity risk, and only a small or no effect on birth weight. A
recent trial showed, however, that benefits of antenatal iron
supplementation on maternal and neonatal health vary by
maternal iron status, with substantial benefits in iron-defi-
cient women. The benefits of universal iron supplementation
are likely to vary with the prevalence of iron deficiency. As a
consequence, the balance between benefits and risks is proba-
bly more favourable in low-income countries than in high-
income countries despite the higher exposure to infectious
pathogens.
Keywords: anaemia, iron supplementation, low-income
countries, malaria, pregnancy.
Introduction
Despite decades of international and national guidelines rec-
ommending universal iron supplementation in pregnancy
through antenatal care (Table I), coverage remains appal-
lingly low in many countries (Hodgins & D’Agostino, 2014),
probably in part due to continued uncertainty about the
benefits. Although it is generally accepted that universal ante-
natal iron supplementation in most settings results in
improved maternal iron markers, such as haemoglobin con-
centration or serum ferritin concentration (Pe~na-Rosas et al,
2015), there has been inadequate and inconsistent evidence
about whether it leads to better maternal and neonatal health
outcomes, such as maternal mortality, caesarean delivery,
preterm delivery, infant mortality or low birth weight. Even
within the USA, recommendations for prevention of iron
deficiency in pregnancy vary between universal iron supple-
mentation (Centers for Disease Control and Prevention,
2008), various screen-and-treat approaches (American Col-
lege of Obstetricians and Gynecologists, 2008; Institute of
Medicine, 2011), or none of these measures, because the sup-
portive evidence is considered to be insufficient (American
Academy of Family Physicians, 2015; Siu, 2015).
Iron interventions in low-income countries present addi-
tional challenges. First, there are increased concerns about
their safety in populations with a high burden of infections.
Particularly unsettling has been evidence from a randomised
trial to assess the effect of supplementation with iron and
folic acid among young children in Pemba Island, Tanzania.
The trial was prematurely stopped because of excess hospital-
isation and death (Sazawal et al, 2006), reinforcing earlier
concerns (Oppenheimer, 2001) that iron supplementation
can increase rates of infectious diseases, including malaria.
There has since been a vigorous debate about how to safely
administer iron to infants, children and pregnant women liv-
ing in malaria-endemic areas. An expert group convened by
the World Health Organization (WHO) recommended
restriction of supplementation in children but not in preg-
nant women (WHO, 2007).
Second, iron interventions in low-income countries often
have limited efficacy in reducing anaemia. It is often unclear
to what extent this is due to ineffective elimination of iron
deficiency or because anaemia is due to other, highly preva-
lent determinants of anaemia. These factors include
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infections and infection-induced inflammation (intestinal
helminths, tuberculosis, human immunodeficiency virus
(HIV), possibly Helicobacter pylori), other nutritional defi-
ciencies (vitamin A, riboflavin and vitamin B12), and haemo-
globin disorders (sickle cell, thalassaemia, haemoglobin C,
and glucose-6-phosphate dehydrogenase deficiency). Inflam-
mation blocks iron absorption by upregulating hepcidin
(Drakesmith & Prentice, 2012) and additionally blocks ery-
thropoiesis.
Third, infections also affect iron markers independently of
iron status. This hampers the assessment of iron status, both
in individuals and at the population level.
We aim to review the current evidence on the safety and
efficacy of antenatal iron supplementation in low-income
countries.
Iron functions and oxidative stress
Iron is the active element of cofactors in many proteins and
is thus required for numerous biological processes. These
proteins are essential for oxygen transport (haemoglobin),
oxygen storage in muscles (myoglobin), mitochondrial elec-
tron transport for ATP synthesis, steroidogenesis and detoxi-
fication (cytochromes and dehydrogenases), amino acid
metabolism (oxygenases), formation of deoxyribonucleotides
from ribonucleotides (ribonucleotide reductase), conversion
of citrate to citrate in the Krebs cycle (aconitase) and conver-
sion of protoporphyrin IX and iron to haem (ferrochetalase)
among numerous other actions.
In all of these metabolic processes, iron plays a central
role because of its capacity to alternate between reduced (fer-
rous, Fe2+) and oxidised (ferric, Fe3+) states. As a powerful
oxidant, however, iron is also a potential catalyst of forma-
tion of hydroxyl radicals and other reactive oxygen species
(ROS). ROS have a variety of biological functions, including
in innate and adaptive immunity (Weiss, 2002). For example,
nicotinamide adenine dinucleotide phosphate-oxidase
(NADPH oxidase) is a membrane-bound enzyme complex
found in phagosomes, the vesicles formed by neutrophils to
engulf pathogens as part of the phagocytic process. NADPH
oxidase contains two haem groups that play a central role in
catalysing oxygen (O2) to the ROS superoxide anion (O2
•),
a free radical that is used to help kill invading microorgan-
isms, either directly or through its subsequent conversion to
hydrogen peroxide and hypochlorous acid. Iron deficiency is
associated with reduced activity of NADPH oxidase and a
reduced ability to produce hypochlorous acid, whilst
NADPH oxidase activity can be restored by iron supplemen-
tation (Kurtoglu et al, 2003; Paino et al, 2009).
Reactive oxygen species can also have damaging effects.
Superoxide, the precursor of most other ROS, is also a fre-
quent by-product of normal cellular metabolism. It is formed
intracellularly by ‘leakage’ (premature outflow) of electrons
from the mitochondrial respiratory chain or from microso-
mal redox-active enzymes, and their subsequent reaction
with oxygen (e.g., Bhattacharyya et al, 2014). Catalytic con-
version of superoxide by superoxide dismutase results in the
formation of hydrogen peroxide (H2O2), which is relatively
stable in solution. Both superoxide and H2O2 are also pro-
duced extracellularly by NADPH oxidases on cell plasma
membranes of phagocytes, endothelial cells and platelets and
by xanthine oxidase that is primarily released into circulation
by hepatocytes (Forman et al, 2016). Blood H2O2 concentra-
tions range from a possible low of 025 lmol/l to a probable
normal range of 1–5 lmol/l, and a high range of 30–
50 lmol/l in certain disease states or during chronic inflam-
mation (Forman et al, 2016). Reaction of H2O2 with ferrous
iron leads to the hydroxyl radical (•OH), an extremely reac-
tive species that can produce substantial damage to DNA,
lipids and amino acids.
Thus iron is a double-edged sword: although crucial for
many central metabolic pathways and immune mechanisms,
its increased accumulation may cause formation of toxic
molecules and progressive tissue damage (Weiss, 2002).
Table I. World Health Organization guidelines for antenatal iron supplementation (WHO, 2012a,b).
Recommendation* Suggested scheme
Daily oral iron supplementation is recommended as part of the
antenatal care to reduce the risk of low birth weight, maternal
anaemia and iron deficiency
For prevention, give daily supplementation with 30–60 mg iron
throughout pregnancy, starting as early in pregnancy as possible
In settings where anaemia in pregnant women is a severe public health
problem (40% of higher), a daily dose of 60 mg of elemental iron is
preferred over a lower dose
Women with anaemia should be daily supplemented with 120 mg iron
until haemoglobin concentration become normal, followed by the
standard antenatal dose to prevent recurrence of anaemia
In settings where the prevalence of anaemia among pregnant women is
lower than 20%, intermittent use of iron supplements by non-
anaemic pregnant women is recommended to prevent anaemia and
improve gestational outcomes
Non-anaemic pregnant women should receive weekly supplementation
with 120 mg iron throughout pregnancy, starting as early in
pregnancy as possible
*In malaria-endemic areas, provision of iron and folic acid supplements should be implemented in conjunction with measures to prevent, diag-
nose and treat malaria.
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Oxidative stress has also been implicated as a mediating fac-
tor in the development of self-limiting and dose-dependent
adverse effects in the gastrointestinal tract (e.g. constipation,
nausea, vomiting, and epigastric discomfort) due to iron
supplementation (Kumar et al, 2009).
The role of iron in the struggle between host
and pathogens
The metabolic role of iron is not unique to humans: most
life forms utilise iron for a variety of metabolic functions.
Because iron is extremely insoluble at physiological pH, its
resulting scarcity has led to an evolutionary battle for iron
between humans and pathogens (Drakesmith & Prentice,
2012). The human host further restricts the availability of
iron by ensuring its tight binding to chaperone proteins
(e.g., haemoglobin, transferrin, ferritin, lactoferrin), and by
modulating the abundance of these proteins as a defence
against extracellular pathogens that could otherwise cause a
rapidly fatal septicaemia (‘iron withholding hypothesis’).
Thus, infections are associated with a shift of iron from cir-
culation to intracellular storage, as reflected by decreased
serum concentrations of transferrin and iron, and increased
serum concentrations of ferritin.
Under normal physiological conditions, the amount of
extracellular free iron in serum is too low to sustain propa-
gation of bacteria (Weinberg, 1974). To survive, pathogens
have evolved several mechanisms to scavenge host iron
(Skaar, 2010). Bacterial toxins damage host cells, leading to
the release of ferritin or (in case of erythrocytes) haemoglo-
bin. Most bacteria secrete and resorb small proteins (‘side-
rophores’) that bind iron in the environment or
competitively remove iron that is contained in host pro-
teins. Other bacterial pathogens and some parasites (e.g.,
Trichomonas vaginalis, Trypanosoma brucei, Schistosoma
mansoni) have circumvented the iron-availability issue by
acquiring iron through receptor-mediated uptake of trans-
ferrin, lactoferrin, haemopexin, haemoglobin, or
haemoglobin–haptoglobin complexes. The source of iron for
various stages of Plasmodium parasites is unclear. Despite
access to abundant haemoglobin, the intraerythrocytic para-
site appears to lack a haem oxygenase pathway that is
required to degrade host haem and release iron for its own
utilisation, and it remains unknown whether non-enzymatic
degradation of haem occurs inside the parasite (Sigala &
Goldberg, 2014).
The iron withholding process is regulated by hepcidin, a
small peptide hormone that was discovered in 2000 and that
is now known to be the key regulator of body iron home-
ostasis in many vertebrates (Ganz & Nemeth, 2015). Hep-
cidin is mostly produced by hepatocytes and acts by binding
to ferroportin, the transmembrane iron exporter protein and
by inducing its intracellular degradation, thus inhibiting cel-
lular iron efflux. Hepcidin synthesis is greatly reduced by
iron deficiency, causing increased absorption in enterocytes
of ingested iron. In contrast, hepcidin is greatly increased by
inflammation, which causes reduced iron absorption and a
blockage of macrophage recycling of iron that would other-
wise be available for erythropoiesis and other metabolic pro-
cesses.
By diverting iron toward macrophages, the host provides
an iron-rich intracellular environment that possibly favours
the proliferation of pathogens, such as Mycobacterium tuber-
culosis and Salmonella species, that are able to survive, prolif-
erate and disseminate throughout the body in macrophages
(Drakesmith & Prentice, 2012).
Antenatal iron requirements in low-income
countries
The prevalence of iron deficiency in pregnant women often
exceeds 50% in low-income countries. In addition to the
effects of inflammation in blocking iron uptake, iron defi-
ciency occurs because the diets of poor people are monoto-
nous, low in animal food sources, and primarily based on
unrefined cereals, grains and legume seeds. Although these
foods have reasonable iron content, they also contain high
concentrations of phytate. This phosphate-storage molecule
occurs naturally in seeds (including grains, pulses, nuts, seeds
in fruits and vegetables) and binds with iron to form insol-
uble complexes that are not absorbed in the intestine. In
addition, phenolic compounds found in tea, coffee and
numerous foods (Quideau et al, 2011), including the seed
coat of many varieties of sorghum, beans and millet, bind
iron and inhibit iron absorption. Calcium also restricts iron
availability for absorption, an issue that is particularly impor-
tant in Mesoamerica where calcium-containing lime is added
during the process of maize preparation (‘nixtamalisation’).
Thus the absorption of iron from a simple, monotonous diet
as is customary in rural, poor populations is at maximum
5% (Food and Agriculture Organization of the United
Nations [FAO]/WHO, 1988). As a consequence, the dietary
iron intake levels that are required to meet the physiological
iron requirements of the poor in low-income countries is
much higher than those with diets that are typical in devel-
oped countries.
Iron demands are further increased by losses due to
chronic bleeding from intestinal wounds caused by helminth
infections (hookworm, Trichuris trichuria and Schistosoma
spp.). Malaria is an important cause of anaemia by inducing
haemolysis and supressing erythropoiesis under the influence
of inflammation, but it does not normally cause body iron
loss: following phagocytosis of erythrocytes, iron is retained
in macrophages, whilst iron contained in freely circulating
haemoglobin and haem following intravascular haemolysis is
recycled by haptoglobin and haemopexin, respectively. How-
ever, some iron may be immobilised in haemozoin, an insol-
uble crystalline pigment formed by Plasmodium parasites as a
degradation product from digested haemoglobin, and iron
may be lost in individuals with glucose-6-phosphate
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dehydrogenase deficiency who suffer haemoglobinuria follow-
ing treatment with oxidant drugs.
Due to dietary deficiencies and helminth infections, most
women in low-income countries start their pregnancies with
absent or marginal iron stores. Because of the cessation of
menstruation during pregnancy, iron requirements initially
decrease in the first trimester compared to the pre-pregnancy
state, but they increase dramatically thereafter to meet the
additional demands for iron deposition in the foetus,
placenta and umbilicus, as well as the increase in maternal
erythrocyte mass (Trumbo et al, 2001). Compared to the
non-pregnant state, however, iron absorption is markedly
suppressed during the first trimester of pregnancy (Svanberg,
1975), perhaps due in part to reduced iron needs, but there
is also evidence that erythropoiesis is suppressed under the
influence of blunted erythropoietin production and receptiv-
ity in the first part of pregnancy (Beguin et al, 1991). The
functional significance or evolutionary survival benefit of this
suppressed iron absorption is unknown, but it has been spec-
ulated that a large bolus of supplemental iron may over-
whelm the mechanisms to restrict iron absorption, which
theoretically causes risks to the fetus because iron may be a
weak mutagen (Weinberg, 2010). In any case, it suggests that
iron supplementation during the first trimester of pregnancy
may have limited efficacy.
With normal pregnancy, maternal plasma volume expands
between 6 and 34 weeks of gestation. This plasma volume
expansion is followed by an increase in erythrocyte mass,
which starts at 8 weeks of pregnancy and continues in the
second and third trimesters. Plasma expansion exceeds ery-
throcyte mass, and the resulting haemodilution is believed to
be a physiological adaptation to pregnancy, allowing delivery
of nutrients to the foetus, protection of the mother from
hypotension, and a reduction of the risks associated with
haemorrhage at delivery (Gaiser, 2014).
The amount of iron needed for the expansion of erythro-
cyte mass is contentious. Iron supplementation will boost
this expansion, and thus increase haemoglobin concentra-
tions in the second and third trimester. As a consequence,
the estimated iron needs are directly dependent on the cut-
off value for haemoglobin concentration (Trumbo et al,
2001). Reference values for haemoglobin concentration in
pregnancy are not defined by functional criteria, but have
been derived from samples of iron-supplemented pregnant
women in the developed countries (WHO, 1968). Against
this background, it is perhaps not surprising that many stud-
ies have found that antenatal iron supplementation produces
increased maternal haemoglobin concentrations and a
reduced risk of anaemia at term. However, the functional
significance of this haematological response has long been
questioned (Beaton, 2000; Rush, 2000; Rioux & LeBlanc,
2007). It is notable that optimal pregnancy outcomes in
terms of birth weight and pre-term labour occur at a mid-
pregnancy haemoglobin of between 95 and 105 g/l (Steer,
2000), which is actually lower than the current definition of
anaemia. The issue is even further complicated when consid-
ering that the distribution of haemoglobin concentration is
known to vary independently of iron status in association
with residential altitude, smoking, ethnicity and genetic fac-
tors (WHO, 2011; New & Wirth, 2015).
Safety of antenatal iron interventions in
malaria-endemic settings
In 2007, 547 million pregnancies occurred in areas with
stable P. falciparum transmission and a further 705 million
in areas with low malaria transmission or with P. vivax only
(Dellicour et al, 2010). Even a small increase in malaria risk
in pregnant women would probably have major public health
implications, given the high prevalence of Plasmodium infec-
tion in many areas and the deleterious effects of infection on
both maternal outcomes (severe anaemia, death) and birth
outcomes (reduced birth weight, intrauterine growth retarda-
tion, preterm delivery, increased neonatal mortality).
In highly endemic areas, most pregnant women are in a
state of premunition, whereby infection occurs without
symptoms or signs other than a reduction in haemoglobin
concentration by 10–20 g/l. The immunity resulting from
frequent exposure to infectious mosquito bites is slowly
acquired and it is sufficient to control but not prevent infec-
tion in adolescents and adults. In pregnancy, the acquired
immunity is transiently reduced, particularly in primiparae
and in the first and second trimesters of pregnancy (Brabin,
1983; Desai et al, 2007). Left untreated, asymptomatic Plas-
modium infections may persist for months. The prevalence
and density of parasitaemia, as well as the level of infection-
induced inflammation, are dependent on previous exposure
to infection. To avoid being filtered through the spleen,
where it would be cleared from the bloodstream and killed,
P. falciparum adheres to chondroitin sulfate A in the placen-
tal intervillous space (Fried & Duffy, 1996), thus leading to
the aggregation of parasitized erythrocytes or haemozoin that
can be undetectable in peripheral blood smears. In condi-
tions of low, seasonal transmission, a state of premunition is
often not attained.
In a systematic review of 28 observational studies, iron
deficiency (indicated by circulating ferritin concentration)
was found to be associated with protection against Plasmod-
ium infection in pregnancy (Sangare et al, 2014).
In vitro studies have shown that P. falciparum is less effi-
cient in parasitizing erythrocytes from iron-deficient donors
than from iron-replete donors (Clark et al, 2014a,b). The
same group has recently shown this to be true in Gambian
children and that it applies both to laboratory and local clin-
ical strains of P. falciparum (Goheen et al, 2016). They have
further shown that young erythrocytes are more susceptible
to invasion and propagation by P. falciparum merozoites
than mature erythrocytes (Clark et al, 2014a,b; Goheen et al,
2016). Seven weeks of iron supplementation completely abro-
gated the protection offered by iron deficiency anaemia in
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both Gambian children (Goheen et al, 2016) and pregnant
Gambian women (Drs Goheen, Bah & Cerami, MRC Unit
The Gambia, Banjul, The Gambia, personal communication).
These results indicate that the increased erythropoiesis and
thus, the greater availability of young erythrocytes in
response to iron supplementation leads to a transient
increase in P. falciparum malaria risk in iron-deficient indi-
viduals but not in their iron-replete peers. These findings
also corroborate the report of a randomised trial supplemen-
tation in Tanzania, which showed that iron-containing mul-
tiple micronutrients increased falciparum malaria rates by
41% in children with confirmed iron deficiency, whereas
there was no evident effect in their iron-replete peers (Veene-
mans et al, 2011). In addition, it was found in this trial that
the excess risk of malaria was most pronounced in the first
50 days of supplementation (Veenemans et al, 2011). These
studies suggest that women are most susceptible to an iron-
induced risk of malaria in the second half of pregnancy,
when iron requirements and iron absorption are very high,
and erythropoiesis is elevated.
Alternatively, it has been postulated that the excess malaria
risk due to supplemental iron is mediated by a transient pro-
duction after each supplemental dose of non-transferrin
bound iron (NTBI), i.e. plasma iron species bound to ligands
other than transferrin (e.g. citrate, albumin). Because iron
binds to these ligands with less affinity than to transferrin,
NTBI may be more available to circulating parasites than
transferrin-bound iron (Clark et al, 2013). This line of evi-
dence would suggest that women in the second half of preg-
nancy are at increased risk compared to their pre-pregnancy
state or in the first half of pregnancy, because iron absorp-
tion and thus, the possible production of NTBI due to iron
supplementation may be more pronounced in individuals
with iron deficiency than in those who are iron replete (Brit-
tenham et al, 2014). However, in contrast to the strong evi-
dence cited above for the transient reticulocytosis as the
main driver of increased malaria risk, there is no direct evi-
dence in support of the NTBI hypothesis.
In their systematic review Sangare et al (2014) found one
single study from Asia that assessed the association between
iron supplementation and P. vivax infection. In this prospec-
tive cohort study, supplementation with iron and folic acid
for less than 30 days was associated with an increased risk
P. vixax parasitaemia. No effect was found for longer supple-
mentation periods. P. vivax has a stronger preference than
P. falciparum for reticulocytes, suggesting a greater suscepti-
bility to iron-induced malaria risk.
The systematic review also identified two randomised tri-
als (Menendez et al, 1994; Ndyomugyenyi & Magnussen,
2000) that assessed the effect of iron supplementation on
malaria risk in pregnancy. Both were published before the
publication of the CONSORT guidelines and were rated as
low quality, mostly because allocation concealment was not
described (Sangare et al, 2014). No routine medical malaria
prevention was used in these trials, and they were
conducted before the wide-scale introduction of insecticide-
treated nets. In The Gambia (Menendez et al, 1994), where
malaria is highly seasonal, multigravidae received daily ante-
natal supplementation with iron (60 mg elemental iron as
ferrous sulphate) or its placebo; all women received folic
acid (5 mg/day). In Uganda (Ndyomugyenyi & Magnussen,
2000), where malaria transmission is stable, primiparae
received oral supplementation with either iron (120 mg ele-
mental iron daily as dextran) and folic acid (5 mg weekly),
or control. Both trials failed to find evidence that iron sup-
plementation caused an increased risk of Plasmodium infec-
tion.
A second systematic review (Pe~na-Rosas et al, 2012) iden-
tified and included another trial (Fleming et al, 1986) that
had been excluded in an earlier version of the same review
(Pe~na-Rosas & Viteri, 2009) because of the high risk of bias
due to incomplete outcome data. In this trial, iron supple-
mentation in Nigerian primigravidae produced an elevated
nonsignificant risk of infection (Fleming et al, 1986).
Two well-conducted randomised trials (Etheredge et al,
2015; Mwangi et al, 2015) were published after these sys-
tematic reviews. Table II compares the key characteristics
and findings from these trials. Neither study found an effect
of antenatal oral iron supplementation on Plasmodium
infection at delivery. A limitation of the Tanzanian trial
(Etheredge et al, 2015) was that women were at low risk of
Plasmodium infection, because the study was conducted in
an urban, low-transmission area; women were iron-replete
and non-anaemic at enrolment; and in the intervention per-
iod, they attended a monthly clinic, received intermittent
preventive treatment of malaria, vouchers for insecticide-
treated nets (coverage: 89%), and care for incident malaria.
As a consequence, the malaria risk was low (67% vs. 65%
in the iron and placebo groups, respectively) and the 95%
confidence interval (CI) of the effect of iron on Plasmodium
risk was wide (risk ratio: 3%, 95% CI: 35% to 65%). In
addition, because women with anaemia, iron deficiency and
HIV infection were excluded, the results cannot be extrapo-
lated to populations with a high prevalence in these condi-
tions.
By contrast, the risk of Plasmodium infection at delivery
was high in the Kenyan trial (Mwangi et al, 2015) (509%
vs. 521% in the iron and placebo groups, respectively), and
the upper limit of 95% CI of the effect of iron excluded an
increase in the risk of Plasmodium infection beyond 95%.
Iron deficiency was highly prevalent in the study population
(60% prevalence at baseline), whilst few women (16%) pos-
sessed insecticide-impregnated mosquito nets. There was no
evidence that intervention effects on Plasmodium infection
risk were modified by gravida status, maternal age, HIV
infection, anaemia or iron status at baseline. The baseline
characteristics of the study population were typical for preg-
nant women in many rural settings in low-income coun-
tries, so that the results apply to a more heterogeneous
population than those from the Tanzanian trial, and to
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conditions with low coverage of insecticide-impregnated
mosquito nets.
A limitation in the interpretation of the Kenyan trial was
that incidental episodes of malaria or other illnesses during
pregnancy were not monitored. Data on the use of intermit-
tent preventive treatment were nonetheless obtained from
antenatal health booklets that women kept and handed in
after the intervention period. There was no evidence that the
effect on Plasmodium infection risk was modified by inter-
mittent preventive treatment (P-value interaction: 091), even
in women who had not received a single dose of intermittent
preventive treatment (Plasmodium infection risk: 410% vs.
454%; difference 43%, 95% CI: 285% to 198%). This
is important because coverage of intermittent preventive
treatment in pregnancy remains low in Africa: in 2014, only
17% of pregnant women received the minimum of three rec-
ommended doses (Table III).
In summary, the concern that antenatal iron supplementa-
tion leads to increased maternal P. falciparum infection is
not supported by epidemiological evidence, at least with a
daily supplemental dose of 60 mg as iron ferrous salts. This
finding and the difference from the increased malaria rates in
young children is most likely explained by greater levels of
acquired immunity in adults than in young children in
malaria-endemic settings. More work is needed to evaluate
effects on P. vivax, which often occurs at lower levels of
endemicity, and has a stronger preference for reticulocytes
than P. falciparum.
Antenatal iron interventions and bacterial
infections
Recent studies indicate that iron interventions can increase
the susceptibility to both systemic and enteric infections,
even though the health importance of these findings in preg-
nancy requires further study.
Ex vivo studies have illustrated that oral supplementation
at doses recommended for prevention of iron deficiency can
potentially undermine innate immunity that is associated
with iron withholding. Adult male volunteers were given oral
supplementation with iron (2 mg/kg iron as ferrous sulfate),
and ex vivo growth of sentinel bacteria species was assessed
Table II. Key characteristics and selected results of two randomised trials to assess the effect of supplementation with iron on maternal Plasmod-
ium infection risk at birth.
Tanzania trial (Etheredge et al, 2015) Kenya trial (Mwangi et al, 2015)
n 1500 470
Study population and design features
Setting Urban Rural, poor
Malaria transmission Low High
Chemoprevention* As per standard care As per routine care
In possession of insecticide-treated net 885% iron group versus 889% placebo group 152% iron group versus 159% placebo group
Duration of intervention From ≤27 weeks of gestational age (by date of
last menstrual period) until delivery
From 13 to 23 weeks of gestational age
(by ultrasound
examination) until 1 month postpartum
Iron-deficient, anaemic women Excluded Included if haemoglobin concentration >90 g/l
HIV-infected women Excluded Included
Intervention 60 mg elemental iron as ferrous sulphate or
placebo
60 mg elemental iron as ferrous fumarate or
placebo
Blinding to intervention Tablets (do not mask iron taste) Capsules, opaque
Adherence assessment Monthly tablet counts Swallowing of supplements was daily observed
Outcomes
Plasmodium infection risk at birth† 67% iron group versus 65% placebo group
Risk difference: 02%
Risk ratio: 3%, 95% CI: 35% to 65% (P = 089)
509% iron group versus 521% placebo group
Risk difference: 12%
(95% CI: 118% to 95%)
Mean birth weight 3155 g versus 3137 g; difference: 26 g (P = 089) Difference: 150 g, 95% CI: 56 g to 244 g
(P = 0002)
Preterm birth risk‡ 150% iron group versus 165% placebo group
Risk difference: 15%
Risk ratio: 9%, 95% CI: 29% to 17%
(P = 046)
91% iron group versus 162% placebo group
Risk difference: 71%, 95% CI: 132%
to 11% (P = 002)
*Intermittent preventive treatment with sulfadoxine-pyrimethamine.
†Primary outcome, defined by histopathological examination and polymerase chain reaction (PCR) analysis of placental biopsies (Etheredge et al,
2015) or 1 or more positive results for (i) the presence of parasite lactate dehydrogenase (pLDH) or histidine-rich protein II (HRP2) in plasma,
or (ii) by placental histopathology, or (iii) P. falciparum DNA in maternal erythrocytes from venous or placental blood by PCR test (Mwangi
et al, 2015).
‡Preterm birth: gestational age <37 weeks.
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in sera collected before and at various time points after sup-
plementation (Cross et al, 2015). Growth of Staphylococcus
aureus, which preferentially scavenges haem iron, was unaf-
fected. By contrast, Escherichia coli, Yersinia enterocolitica,
Salmonella enterica serovar Typhimurium, and Staphylococcus
epidermidis showed markedly elevated growth in response to
iron supplementation. Growth rates were strongly correlated
with transferrin saturation, which transiently increased from
421% to 757%, but the effects may also have been mediated
at least in part by transient production of NTBI.
Iron supplementation and iron fortification have also been
shown to adversely modify the abundance and virulence of
pathogenic enteric bacteria (Zimmermann et al, 2010; Kort-
man et al, 2012; Dostal et al, 2014; Jaeggi et al, 2015).
Safety of antenatal iron interventions in
women with high haemoglobin concentration
There are concerns that antenatal iron supplementation in
women with high haemoglobin concentration (above
130–135 g/l) in the second and third trimesters can lead to
an increased risk of adverse pregnancy outcome, such as pre-
mature delivery and low birth weight (Pe~na-Rosas & Viteri,
2009). Most reports on this association concerned observa-
tional studies e.g. (Murphy et al, 1986; Zhou et al, 1998;
Steer, 2000; Xiong et al, 2000; Casanueva & Viteri, 2003),
which may be confounded because high haemoglobin con-
centrations may also be due to other pregnancy complica-
tions (e.g., a failure of the normal pregnancy-induced
physiological plasma volume expansion, pre-eclampsia,
hypertension) that can cause maternal and perinatal deaths.
In a randomised trial in Iran, antenatal supplementation
with iron (50 mg as ferrous sulphate) in women with hae-
moglobin concentration ≥132 g/l in the early stage of the
second trimester resulted in an increased risk of women with
hypertension disorder [27% vs. 08%, difference: 19% (95%
CI: 02% to 41%)] and small-for-gestational age neonates
[154% vs. 101%, difference: 53% (95% CI: 05–102%)]
(Ziaei et al, 2007). However, in a recent large trial among
Chinese pregnant women with haemoglobin concentration
>145 g/l at enrolment (gestational age <20 weeks), supple-
mentation with iron (30 mg as ferrous fumarate) increased
birth weight by 91 g (95% CI: 3–180 g) (Wang et al, 2016).
It should also be noted that in most low-income countries,
women with haemoglobin concentrations >130 g/l constitute
a small proportion of the total number of pregnancies.
Table III. Efficacy and coverage of key interventions recommended by the World Health Organization (WHO) to prevent malaria* in African
pregnant women.
Intervention Policy Protective efficacy against malaria Coverage
Insecticide-treated
mosquito nets
In endemic areas with intense
malaria transmission, all pregnant
women should receive, as early as
possible in pregnancy, one long-
lasting insecticidal net through
immunisation and antenatal care
visits†
Compared with no nets (Gamble
et al, 2006):
• Risk of peripheral parasitaemia at
delivery reduced by 23%
(95% CI: 14–48%; I2: 0%)
• Parasite density reduced by 7%
(95% CI: 11% to 23%, I2: 42%)
• Placental parasitaemia reduced by
21% (95% CI: 2–37%, I2: 35%)
In 2015, 55% of the population of
sub-Saharan Africa was sleeping
under an impregnated mosquito
net (WHO, 2015)
Intermittent preventive
treatment (IPT) with
sulfadoxine-pyrimethamine
In areas with moderate to high
malaria transmission in Africa,
delivery of sulfadoxine-
pyrimethamine is recommended at
each of the three recommended
antenatal care visits after the first
trimester, with a minimum of
three doses received during each
pregnancy (WHO, 2014)
Reduction in risk compared to
placebo/no intervention
(Radeva-Petrova et al, 2014):†
• Maternal parasitaemia
(i.e. presence of asexual stage
parasites in thick smears in
peripheral, placental, or cord
blood): 62% (95% CI: 41–76%,
I2: 86%)
• Malarial illness (history of fever
episodes prior to delivery): 76%
(95% CI: 12% to 95%, 1 study
only)
• Placental parasitaemia: 55% (95%
CI: 39–67%, I2: 54%)
• Cord blood parasitaemia: 53%
(95% CI: 1% to 78%, I2: 40%)
Only 52% of eligible pregnant
women received at least one dose
of IPT in pregnancy in 2014, while
40% received two or more doses
and 17% received three or more
doses (WHO, 2015)
*Effects on malaria-associated outcome such as maternal anaemia, birth weight and perinatal mortality are not listed because they were outside
the scope of the current review.
†Universal access to and use of long-lasting insecticidal nets remains the goal for all people at risk of malaria.
Review
ª 2017 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd. 7
Benefits of antenatal iron interventions
Iron deficiency is the primary cause of anaemia in all regions
of the world (Kassebaum et al, 2014), and iron interventions
can prevent 20–50% of the prevalence of anaemia in preg-
nant women (Black et al, 2013; Black, 2014; WHO, 2015).
Anaemia is a moderate-to-severe public health problem in
pregnancy in virtually all countries worldwide, affecting 46%,
49%, 39% and 25% of pregnant women in WHO regions of
Africa, Southeast Asia, the Eastern Mediterranean and Ameri-
cas, respectively (WHO, 2015).
Based on observational studies on the association between
anaemia and mortality, iron deficiency in pregnancy has been
estimated to cause 115 000 maternal deaths and 591 000
perinatal deaths worldwide. The associated loss of healthy life
years amounts to almost 20 million disability-adjusted life
years (DALYs) from perinatal causes and almost 35 million
from maternal causes (Stoltzfus et al, 2004). Observational
studies on the relationship between anaemia and maternal
mortality typically suffer from severe methodological short-
comings (reviewed by Rush, 2000) that preclude solid con-
clusions about causality.
A recent meta-analysis of randomised trials (Pe~na-Rosas
et al, 2012) was undertaken to close the knowledge gaps on
the causal effects of antenatal iron supplementation on
maternal and neonatal health outcomes. Key results are sum-
marised in Table IV.
First, antenatal iron supplementation was found to reduce
the risk of a transfusion being required by the mother by 39%
and the risk of severe anaemia at postpartum (haemoglobin
concentration <80 g/l) by 96%. We hypothesize that effects on
these outcomes are mediated by two possible mechanisms.
First, in women with iron deficiency, iron supplementation
can reduce the severity of blood loss at or after delivery, as
indicated by a study showing that the severity of anaemia
before a spontaneous vaginal delivery was associated with the
amount of blood loss at delivery and the immediate postpar-
tum period (Kavle et al, 2008). Second, in women with prena-
tal iron deficiency anaemia, iron supplementation is likely to
raise pre-delivery haemoglobin concentrations, thus reducing
the risk of severe anaemia following perinatal blood loss. In
both cases, iron supplementation would provide women with
an increased chance of surviving maternal haemorrhage, which
is the leading cause of maternal deaths during pregnancy
(GBD 2013 Mortality and Causes of Death Collaborators,
2015). Unfortunately, in the meta-analysis referenced above
(Pe~na-Rosas et al, 2012), the effect on maternal deaths was not
estimable because of a lack of data.
Table IV. Effect of daily antenatal iron supplementation on selected outcomes, meta-analysis of randomised controlled trials (Pe~na-Rosas et al,
2012).*
Outcome
Participants,
n (trials, n) Summary measure Effect (95% CI) I2
Maternal haemoglobin concentration at or near term
(at 34 weeks gestation or more)
3704 (19) Mean difference 89 g/l (70–108 g/l) 087
Maternal haemoglobin concentration within 6 weeks
postpartum, g/l
956 (7) Mean difference 76 g/l (55–97 g/l) 04
Maternal anaemia at term (haemoglobin concentration
<110 g/l at 37 weeks of gestation or later)
2199 (14) Risk ratio 030 (019–046) 08
Maternal severe anaemia at postpartum (haemoglobin
concentration <80 g/l)
1339 (8) Risk ratio 004 (001–028) 0
Maternal iron deficiency at term (as defined by
researchers, based on any indicator of iron status
at 37 weeks gestation or more)
1256 (7) Risk ratio 043 (027–066) 085
Maternal high haemoglobin concentrations at or
near term (haemoglobin concentration >130 g/l
at 34 weeks gestation or later)
4850 (9) Risk ratio 308 (128–741) 096
Transfusion provided to the mother 3453 (3) Risk ratio 061 (038–096) 0
Birth weight 9385 (14) Mean difference 308 g (59–557 g) 023
Low birth weight (<25 kg) 8480 (11) Risk ratio 081 (068–097) 016
Premature birth (<37 weeks of gestation) 10 148 (13) Risk ratio 088 (077–101) 0
Infant haemoglobin concentration within the first
6 months; counting the last reported measure
after birth within this period
533 (2) Mean difference 13 g/l (81 to 56 g/l) 089
Infant serum ferritin concentration in the first
6 months; counting the last reported measure
after birth within this period
197 (1) Mean difference 110 lg/l (437–1763 lg/l) NA
NA, not applicable; 95% CI, 95% confidence interval.
*Any supplements containing iron versus same supplements without iron or no treatment.
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Second, the effect of antenatal iron supplementation on
pre-partum and post-partum haemoglobin concentrations
was generally positive but varied greatly in size between trials
(as shown by the high values for I2, the percentage of total
variation across studies that is due to heterogeneity). Sub-
group analysis suggested that the effect of intervention on
maternal anaemia at term was less pronounced in settings
with malaria than in those without malaria (risk reduction:
39% vs. 82%, P-interaction: 00006). This finding can be
explained at least in part by evidence that malaria-induced
inflammation reduces iron absorption under the influence of
upregulated production of hepcidin (Verhoef, 2010; Spottis-
woode et al, 2012).
Third, the meta-analysis found antenatal iron supplemen-
tation increased birth weight by 31 g, and it decreased the
risk of low birth weight by 19%. This effect on birth weight
is small compared to the normal variability in birth weight
(the usual standard deviation is ~450 g) and corroborates
findings from other recent meta-analyses that found no effect
on birth weight (Vucic et al, 2013) or an increase of only
41 g (Haider et al, 2013).
A major limitation of these meta-analyses is that they were
based on randomised trials that excluded women with anae-
mia or iron deficiency; or women received iron as rescue ther-
apy during intervention (including those in the placebo
group); or initial anaemia status and iron status had not been
specified. As a consequence, the results do not apply to iron-
deficient women, and they cannot be extrapolated to popula-
tions with a high prevalence of iron deficiency or anaemia.
To our knowledge, the study in Kenyan women cited pre-
viously (Mwangi et al, 2015) is the only placebo-controlled
trial conducted so far that enrolled women with iron defi-
ciency and anaemia at baseline. In that trial, antenatal iron
supplementation increased birth weight by 150 g (95% CI:
56–244 g). It was anticipated that iron absorption and thus
effects of administered iron would depend on baseline iron
status. Subgroup analysis confirmed that the effect of iron on
birth weight was larger in women with iron deficiency at
baseline than in those who were initially iron-replete (234 g
vs. 39 g; difference, 195 g; 95% CI, 3 to 393 g; P = 005).
The risk of low birth weight decreased by 58%. The absolute
risk reduction was 60% (95% CI, 08–111%), indicating
that, on average, 168 women (95% CI, 90–613%) needed
to receive supplementation to prevent 1 case of low birth
weight.
Additional results indicated that the improvements in
birth weight were achieved at least in part through an
increased gestational duration, a decreased risk of prematu-
rity and an increased neonatal length (Mwangi et al, 2015).
Lastly, antenatal iron supplementation improved neonatal
iron stores at 1 month postpartum, thus probably delaying
the age at which iron deficiency will develop during infancy.
Consistent with the effect on birth weight, the effect on
plasma ferritin concentrations in neonates varies by initial
iron status of the mother (Mwangi et al, 2015), with larger
effects in children with mothers who were iron deficient at
baseline (unpublished observations).
Screen and treat: an alternative to universal
iron supplementation in pregnancy?
As an alternative to universal supplementation, iron supple-
mentation could be restricted to pregnant women who are
screened and diagnosed with iron deficiency during antenatal
clinics. As minimum requirements, these tests should be low-
cost, practicable in field conditions and provide immediate
results at the point of care. At present, the only two diagnos-
tic tests that could possibly meet these criteria are haemoglo-
bin concentration and whole blood zinc protoporphyrin
content (commonly expressed as its molar ratio to haem).
Both markers have the disadvantage that they are influenced
by inflammation independently of iron status. Their diagnos-
tic utility was recently evaluated in Kenyan pregnant women
without inflammation, Plasmodium infection or HIV infec-
tion (Mwangi et al, 2014). When these markers are used for
screening purposes in settings with a moderate or high
prevalence of iron deficiency, however, their ability to dis-
criminate between individuals with and without iron defi-
ciency was found to be inadequate, whether used alone or in
combination. When applied to all women (i.e. including
inflammation and infections), their diagnostic performance
would presumably have been even worse.
There is no universally accepted method for accounting
for inflammation when estimating iron status using ferritin
values. In low-income countries, the WHO recommends
measuring inflammation markers, such as C-reactive protein
(CRP) and/or a-1-acid glycoprotein (AGP). These are used
together with ferritin to exclude inflamed individuals from
analysis or to alter the cut-off of ferritin used to define defi-
ciency. Recently, the Biomarkers Reflecting Inflammation
and Nutrition Determinants of Anaemia (BRINDA) project
proposed possible methods to address inflammation and
other potential confounders of ferritin (Suchdev et al, 2016).
The quantitative assessment of circulating concentrations of
CRP and AGP allows for adjustment of ferritin concentration
for the effect of inflammation (Suchdev et al, 2016; Thurn-
ham & Northrop-Clewes, 2016). In addition, point-of-care
tests are rapidly developing, with quantitative tests already
being commercially available for circulating concentrations of
ferritin and C-reactive protein. Access to such tests to allow
diagnosis of iron deficiency in low-income countries is highly
desirable because screening based on plasma ferritin concen-
tration has been shown to better predict beneficial responses
to iron interventions than screening based on anaemia
(Mwangi et al, 2015).
Discussion and conclusions
As with any intervention, uncertainty about the safety of
antenatal iron supplementation is inevitable, because
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conclusive proof of safety would require that randomised
controlled trials in a wide variety of conditions consistently
produce 95% CIs with upper limits that exclude an increased
risk of adverse effects. In other words, trials would need to
show that antenatal iron supplementation actually protects
against Plasmodium infection.
In the present review, we found no evidence that antenatal
iron supplementation at a daily dose of 60 mg/day leads to
an increased risk of maternal Plasmodium infection. This
finding should not be extrapolated to young children, who in
endemic areas have lower levels of acquired immunity, and
for whom there is substantial evidence that iron supplemen-
tation can increase the incidence of malaria.
The trial in Kenyan women (Mwangi et al, 2015) provides
unique and compelling evidence, indicated by multiple mark-
ers, that antenatal supplementation with iron provides
maternal and neonatal health benefits in iron-deficient preg-
nant women that vary from those in their iron-replete coun-
terparts. Thus, the benefits of universal iron supplementation
are likely to vary with the prevalence of iron deficiency, and
also probably exceed the relatively small benefits found in
earlier meta-analyses (Pe~na-Rosas et al, 2012; Haider et al,
2013). In settings where health personnel make decisions for
individual women without diagnostic tests, they need to con-
sider the a priori probability of iron deficiency. In most con-
ditions in low-income countries, this probably is high and
may exceed 50%.
Thus, the balance between benefits and risks is probably
more favourable in low-income countries than in high-
income countries. It should be noted that even in women
with iron deficiency in their second pregnancy trimester,
antenatal iron supplementation increased birth weight by
234 g without evidence of an increased risk of malaria
(Mwangi et al, 2015).
Considering the continued efficacy of intermittent preven-
tive treatment and insecticide-impregnated mosquito nets
(Table III), it is prudent that iron supplementation is pro-
vided to pregnant women in conjunction with measures to
prevent, diagnose and treat malaria, as recommended by the
WHO. The study by Mwangi et al (2015) suggests, however,
that the benefit outweighed the risk even in conditions of
poor coverage of preventive measures.
Uncertainties remain about the safety of antenatal iron
supplementation in conditions with P. vivax transmission,
about the health importance of studies suggesting that iron
supplementation can (in ex vivo experiments) stimulate the
growth of potential pathogens in serum, and about the bal-
ance of benefits and risks of antenatal supplementation in
malaria-endemic areas at doses of iron exceeding 60 mg/day.
This is particularly important in view of the WHO recom-
mendations of using a daily treatment dose of 120 mg in
women with anaemia, and a weekly dose of 120 mg in non-
anaemic pregnant women (Table I).
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